In this cohort study of patients with cirrhosis who were receiving furosemide and spironolactone, SGLT-2 inhibitor use was associated with a lower risk of serious liver events, defined as incidence of ascites, variceal development, hyponatremia, or all-cause mortality. The gene discussed is SLC5A2; the disease is Cirrhosis.